Literature DB >> 11338580

Enantiomeric analysis of pharmaceutical compounds by ion/molecule reactions.

G Grigorean1, C B Lebrilla.   

Abstract

Protonated complexes involving cyclodextrin hosts and guest compounds that are pharmacologically important are produced in the gas phase and reacted with a gaseous amine. The guest is exchanged to produce a new protonated complex with the amine. The reaction is enantioselective and is used to develop a method for determining enantiomeric excess using only mass spectrometry. The pharmaceutical compounds include DOPA, amphetamine, ephedrine, and penicillamine. The presence of more than one reacting species is observed with DOPA and penicillamine. Molecular dynamics calculations are used to understand the nature of the interactions and the possible source of the variations in the reactivities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11338580     DOI: 10.1021/ac001135q

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  11 in total

1.  Evaluation of chiral recognition characteristics of metal and proton complexes of di-o-benzoyl-tartaric acid dibutyl ester and L-tryptophan in the gas phase.

Authors:  Hao-Jie Lu; Yin-Long Guo
Journal:  J Am Soc Mass Spectrom       Date:  2003-06       Impact factor: 3.109

2.  Unexpected behavior of diastereomeric ions in the GasPhase: a stimulus for pondering on ee measurements by ESI-MS.

Authors:  Caterina Fraschetti; Antonello Filippi; Maria Elisa Crestoni; Tadashi Ema; Maurizio Speranza
Journal:  J Am Soc Mass Spectrom       Date:  2013-03-14       Impact factor: 3.109

3.  Probing isomeric differences of phosphorylated carbohydrates through the use of ion/molecule reactions and FT-ICR MS.

Authors:  M D Leavell; Julie A Leary
Journal:  J Am Soc Mass Spectrom       Date:  2003-04       Impact factor: 3.109

4.  Diastereochemical differentiation of beta-amino acids using host-guest complexes studied by Fourier transform ion cyclotron resonance mass spectrometry.

Authors:  Anna R M Hyyryläinen; Jaana M H Pakarinen; Pirjo Vainiotalo; Géza Stájer; Ferenc Fülöp
Journal:  J Am Soc Mass Spectrom       Date:  2007-03-12       Impact factor: 3.109

5.  Noncovalent complexation of monoamine neurotransmitters and related ammonium ions by tetramethoxy tetraglucosylcalix[4]arene.

Authors:  Mika Torvinen; Elina Kalenius; Francesco Sansone; Alessandro Casnati; Janne Jänis
Journal:  J Am Soc Mass Spectrom       Date:  2011-12-01       Impact factor: 3.109

6.  Stereoselective discrimination and quantification of arginine and N-blocked arginine enantiomers by formation and dissociation of calcium-mediated diastereomeric trimer complexes with a chiral reference compound using electrospray ionization-ion trap tandem mass spectrometry.

Authors:  Kevin A Schug; Wolfgang Lindner
Journal:  J Am Soc Mass Spectrom       Date:  2005-03-29       Impact factor: 3.109

7.  Chiral differentiation of some cyclopentane and cyclohexane beta-amino acid enantiomers through ion/molecule reactions.

Authors:  Anna R M Hyyryläinen; Jaana M H Pakarinen; Eniko Forró; Ferenc Fülöp; Pirjo Vainiotalo
Journal:  J Am Soc Mass Spectrom       Date:  2009-02-21       Impact factor: 3.109

8.  Chiral recognition of zinc(II) ion complexes composed of bicyclo[3.3.0] octane-2,6-diol and s-naproxen probed by collisional-induced dissociation.

Authors:  Chong-Tian Yu; Yin-Long Guo; Guo-Qiang Chen; Yu-Wu Zhong
Journal:  J Am Soc Mass Spectrom       Date:  2004-06       Impact factor: 3.109

9.  Stereoselectivity in the collision-activated reactions of gas phase salt complexes.

Authors:  Scott Gronert; Adelaide E Fagin; Keiko Okamoto
Journal:  J Am Soc Mass Spectrom       Date:  2004-10       Impact factor: 3.109

10.  Structural relationships in small molecule interactions governing gas-phase enantioselectivity and zwitterionic formation.

Authors:  Xin Cong; Gregg Czerwieniec; Erica McJimpsey; Seonghee Ahn; Frederic A Troy; Carlito B Lebrilla
Journal:  J Am Soc Mass Spectrom       Date:  2006-02-14       Impact factor: 3.109

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.